India Tightens Grip on GLP-1 Weight-Loss Drugs

The Cliff News | 5 August 2026

New directives have been issued to drug regulators nationwide, mandating intensified surveillance over the supply chain and promotional activities surrounding GLP-1 weight-loss drugs. This move comes in response to growing concerns about the use of surrogate advertising and misleading awareness campaigns that aim to bypass regulations.

In a statement made to the Rajya Sabha on Tuesday, Minister of State for Health Anupriya Patel confirmed that the Central Drugs Standard Control Organisation (CDSCO) has officially approved these glucagon-like peptide-1 (GLP-1) receptor agonists. Their approved uses are exclusively for the treatment of Type 2 diabetes in adults and for managing chronic weight issues in adults who have specific underlying medical conditions.

Strict Dispensing and Usage Guidelines

The minister emphasized that these potent medications are to be dispensed solely under the prescription of qualified specialists, namely endocrinologists or internal medicine physicians. The approved product information for these drugs explicitly includes warnings designed to deter inappropriate use and to mitigate the risks associated with self-medication or unsupervised consumption.

These measures aim to ensure that GLP-1 drugs are utilized only for their intended medical purposes and under professional medical supervision, safeguarding patient health.

Addressing Surrogate Marketing Tactics

Responding directly to inquiries regarding advertisements for weight-loss drugs masquerading as general "awareness" campaigns, and the promotion of GLP-1 drugs through surrogate marketing channels, Ms. Patel highlighted previous regulatory actions. She stated that the CDSCO had issued a comprehensive advisory on March 10, 2026, to all manufacturers, importers, and marketing authorisation holders.

This advisory unequivocally directed all stakeholders to adhere strictly to the provisions of the Drugs and Cosmetics Act. It further mandated that the manufacture, sale, and distribution of these drugs must conform exclusively to their approved indications and the specific conditions under which their permission was granted, thereby cracking down on off-label promotion.